AdvanCell Isotopes is involved in the production and supply of Alpha Emitting Isotopes for Targeted Alpha Therapy for cancer. Targeted Alpha Therapy is a revolutionary treatment that uses alpha-emitting isotopes attached to molecules that deliver cytotoxic radiation direct to tumours, i.e. radiotherapy at the molecular level. AdvanCell’s goal is a safe and effective treatment for patients with multiple forms of cancer, that will become a standard of care.
Location: Australia, New South Wales, Sydney
Employees: 11-50
Total raised: $142.55M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 13.02.2025 | SymBiosis | symbiosis.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.04.2025 | - | $18M | - |
| 10.02.2025 | Series C | $112M | - |
| 24.08.2022 | Series B | $12.55M | - |
Mentions in press and media 9
| Date | Title | Description |
| 02.02.2026 | AdvanCell and 48Hour Discovery Enter Exclusive Agreement to Advance a Lead-212 Radioligand Therapy Program | AdvanCell and 48Hour Discovery Announce Collaboration and Exclusive Licensing Agreement to Develop a Lead-212 Alpha Radioligand Therapy Program We see this program as an important validation of our discovery engine in the radioligand therap... |
| 28.07.2025 | Brandon Capital: Fund Six Closed At Over A$439 Million | Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6), totaling A$439 million. New investors in BB6 include the Western Australia G... |
| 14.04.2025 | AdvanCell Receives $18M in Federal Funding | AdvanCell, a Sydney, Australia-based clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, received $18M in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiat... |
| 10.02.2025 | AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing | Sydney, Australia – 3 February 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This ... |
| 03.02.2025 | AdvanCell Closes US$112M Series C Financing | AdvanCell, a Sydney, Australia-based clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, closed a US$112m Series C financing. The round was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and Sy... |
| 03.02.2025 | AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing | Sydney, Australia – 3 February 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This ... |
| 25.08.2022 | Australia-based AdvanCell closes Series B funding at A$18 million | Sydney, Australia-based radiopharmaceutical company with platform technology for cancer treatment, AdvanCell, closed its Series B funding at A$18 million. The company announced the closure of financing on August 24, 2022. |
| 24.08.2022 | AdvanCell Closes A$18M Series B Funding | AdvanCell, a Sydney, Australia-based radiopharmaceutical company with a platform technology for cancer treatment, closed an A$18m Series B financing. The round was led by Morningside. Anthony Aiudi from Morningside has been appointed to the... |
| - | AdvanCell | “AdvanCell” |